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Abstract: Stable isotope-resolved metabolomics (SIRM) is a powerful tool for understanding disease.
Advances in SIRM techniques have improved isotopic delivery and expanded the workflow from
exclusively in vitro applications to in vivo methodologies to study systemic metabolism. Here, we
report a simple, minimally-invasive and cost-effective method of tracer delivery to study SIRM
in vivo in laboratory mice. Following a brief fasting period, we orally administered a solution of
[U-13C] glucose through a blunt gavage needle without anesthesia, at a physiological dose commonly
used for glucose tolerance tests (2 g/kg bodyweight). We defined isotopic enrichment in plasma
and tissue at 15, 30, 120, and 240 min post-gavage. 13C-labeled glucose peaked in plasma around
15 min post-gavage, followed by period of metabolic decay and clearance until 4 h. We demonstrate
robust enrichment of a variety of central carbon metabolites in the plasma, brain and liver of C57/BL6
mice, including amino acids, neurotransmitters, and glycolytic and tricarboxylic acid (TCA) cycle
intermediates. We then applied this method to study in vivo metabolism in two distinct mouse
models of diseases known to involve dysregulation of glucose metabolism: Alzheimer’s disease and
type II diabetes. By delivering [U-13C] glucose via oral gavage to the 5XFAD Alzheimer’s disease
model and the Lepob/ob type II diabetes model, we were able to resolve significant differences in
multiple central carbon pathways in both model systems, thus providing evidence of the utility of
this method to study diseases with metabolic components. Together, these data clearly demonstrate
the efficacy and efficiency of an oral gavage delivery method, and present a clear time course for 13C
enrichment in plasma, liver and brain of mice following oral gavage of [U-13C] glucose—data we
hope will aid other researchers in their own 13C-glucose metabolomics study design.
Keywords: metabolomics; stable isotope; 13C-glucose; gavage; SIRM; Alzheimer’s disease; diabetes;
brain metabolism
1. Introduction
Traditional techniques in targeted metabolomics provide quantitative analysis of metabolite pools
within a selected network, thus offering a snapshot of overall changes in the metabolome. A more
targeted understanding of a specific pathway can be obtained with a stable isotope labeled substrate,
or isotopic tracer, which offers improved specificity for the pathways and metabolic enzymes involved;
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for example, identifying metabolites downstream of glucose metabolism/catabolism when 13C-glucose
is use as the primary tracer.
Stable isotope-resolved metabolomics (SIRM) couples stable isotope tracing with nuclear magnetic
resonance (NMR) and/or mass spectrometry (MS)-based analyses so that labeling patterns (isotopomers
and isotopologues) of numerous metabolites can be determined for robust and large-scale reconstruction
of metabolic networks [1]. This approach has been successfully applied to cultured cells, mouse models,
tissue models and human patients [2–4]. SIRM has been applied most heavily in cancer research,
where it has been used to elucidate alterations in metabolic networks associated with different cancers,
as well as rare somatic mutations in isocitrate dehydrogenase [5–7], and germline lesions in fumarate
hydratase [8–10] and succinate dehydrogenase [9,11,12].
With added insights through isotopic enrichment, SIRM builds on the foundational metabolomic
methodologies that employ metabolite fractionation by either gas or liquid chromatography (GC; HPLC),
or capillary electrophoresis (CE), followed by mass spectrometry detection [13]. An important
consideration when designing a SIRM study i selecting the appropriate tracer substrate. Selection of the
appropriate stable isotope (e.g., 13C, 15N, 2H, 18O, 34S) and substrate (e.g., glucose, lactate, glutamine,
etc.) should rely upon the desired pathway to be investigated; and more selective analysis of specific
nodes of interest within pathways can be resolved with specific number and position of stable isotopes.
For example, [U-13C] glucose provides broad incorporation throughout central carbon metabolism
pathways, while [1,2-13C] glucose provides specific resolution of oxidative and non-oxidative branches
of the pentose phosphate pathway (PPP). A description of current stable isotope tracers and their
respective utilization(s) is reviewed in detail by Jang, et al. [14]. The unique information gained
through tracer metabolomics can be a powerful tool for biomarker identification and drug discovery,
and aids in both disease profiling as well as mechanistic studies by providing a critical measure of the
functional outcome from a given biological system.
While the majority of SIRM experiments are conducted in vitro, a variety of delivery methods
have also been successfully applied to stable-isotope tracing in vivo. These include single or repeated
injections of isotopic tracers via intraperitoneal (IP) injection, or direct injection into the circulation via
intravenous (IV) infusion [15–18]. While these methods are cost-effective, they sacrifice the physiological
absorption and metabolism for substrates that are normally ingested. Continuous infusions of the
isotopically labeled substrate through cannulation is another common approach [19], as it offers the
benefit of increased depth of labeling in more complex metabolic pathways and simpler interpretation
as a result of achieving constant isotopic enrichment (i.e., isotopic steady state). However, the primary
drawbacks of infusion methods are the significant invasiveness of the procedure, the high level of
technical complexity required, and throughput limitations due to the long time periods required to
test each individual animal. Alternatively, oral administration through ad libitum feeding of a diet
in which the isotope has been incorporated has the advantages of being non-invasive, less stressful,
and conducive to allowing the organism to reach isotopic steady state with ad libitum feeding over
16+ hours [20]. However, it is impossible to control for differences in the timing and amount of food
intake in this ad libitum setting. The method also requires customized animal feed and relatively large
amounts of isotopic label, and is thus quite expensive compared to other methods.
While no administration method is without drawbacks, isotope delivery via an oral gavage is an
attractive strategy to mitigate several of the common limitations described above. The method is simple,
minimally invasive, and requires low amounts of isotopic tracer. A handful of studies have employed
an oral gavage to deliver 13C tracers, mainly fatty acids [21–24] and carbohydrates [25–28]. For example,
one study examined 13C enrichment into glycogen following oral gavage of glucose [26], while another
examined 13C enrichment in liver, small intestine, and skeletal muscle following oral gavages of a
1:1 mixture containing labeled fructose and unlabeled glucose or vice versa [28]. Here, we detail a
simplified, cost-effective method of 13C isotope delivery based on the glucose tolerance test performed
routinely in mouse models. This method produces robust isotopic distribution, with the added
advantage of speed and consistency to improve rigor and reproducibility. We provide a detailed time
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course and labeling patterns for one of the most commonly used tracer substrates, [U-13C] glucose,
in the plasma, liver and brain. Finally, we apply our method in two distinct mouse models of disease
that feature metabolic components, demonstrating lower 13C-glucose enrichment in glycolysis in the
Lepob/ob model of type II diabetes, and decreases in de novo neurotransmitter synthesis in the 5XFAD
mouse model of Alzheimer’s disease.
2. Results
2.1. Experimental Workflow and Stable Isotope Tissue Distribution
For the current experimental workflow, universally labeled ([U-13C]) glucose was delivered to
fasted mice (C57BL/6) via oral gavage (2 g/kg bodyweight). At select time points (15 min, 30 min,
2 h, or 4 h post-gavage), tissues were harvested and prepared for analysis by gas chromatography
mass spectrometry (GCMS) (Figure 1a). Total plasma glucose concentrations followed an expected
time course following the 13C-glucose gavage, with a peak concentration around 15 min and a
return to baseline (fasting) concentrations after 4 h (Figure 1b). Quantification of 13C-glucose in
the plasma showed that by 15 and 30 min, >50% of plasma glucose was fully labeled (13C6; m+6),
and by 4 h post-gavage <5% of circulating glucose was fully labeled (Figure 1c). We next examined
13C enrichment of representative metabolites within pathways of glycolysis, TCA, amino acid and
neurotransmitter synthesis in the plasma, liver and brain of mice gavaged with [U-13C] glucose.
The pathway distribution analysis (Figure 1d) shows the average enrichment per pathway, represented
as donut charts. Distribution of 13C among metabolic pathways varied greatly by tissue, with the
highest incorporation into glycolysis in plasma and liver, which was prevalent at all time points
(Figure 1d, first and second row). However, 13C incorporation in brain 15 min post-gavage was
distributed relatively equally into glycolysis, TCA cycle, amino acid, and neurotransmitter synthesis
pathways, while neurotransmitter synthesis was most prominent at later time points (Figure 1d,
third row). The pathway distribution of 13C within tissues also shifted over time, for example in
brain, where the percent of 13C found in neurotransmitters (glutamate, aspartate, γ-aminobutyric acid
(GABA), and pyroglutamic acid) increased from 23.7% at 15 min to 40.4% at 4 h (Figure 1d, third row).
The time course of fractional enrichment in plasma (Figure S1, Supplementary Material) highlights
13C labeling in metabolites at 15 min, 30 min, 2 h, and 4 h post-gavage. Fractional enrichment in
the labeled isotopologues of glucose show that fully labeled, glucose (m+6) is the most abundant at
15 and 30 min, accounting for nearly 50% of total glucose, and decreases to less than 10% after 2 h
(Figure S1a). Roughly 20% of pyruvate and lactate in the plasma was fully labeled at 15 and 30 min and
decreases thereafter, while citrate and other metabolites associated with the TCA cycle show a slower,
less prevalent enrichment that peaks at 2 h (Figure S1b–d). Together, these data show that the described
method for 13C substrate administration via oral gavage reliably achieves sufficient incorporation into
multiple central carbon pathways (glycolysis, TCA cycle, and amino acid metabolism pathways) in
multiple tissues.
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Figure 1. Experimental design, plasma glucose labeling and 13C pathway distribution analysis after 
oral gavage of [U-13C] glucose. (a) Schematic of metabolomics workflow for usage of stable isotope 
tracer in vivo delivered via oral gavage. Mice were orally gavaged [U-13C] glucose tracer (2 mg/kg 
bodyweight), euthanized 15 min, 30 min, 2 h, or 4 h post-gavage, tissues and plasma promptly 
collected and frozen in liquid nitrogen. Tissues were machine-ground under liquid nitrogen after 
which tissue (or plasma) polar metabolites extracted with MeOH, vacuum dried, derivatized, and 
analyzed via GCMS. Data interpreted using AMDIS and DExSI software for determining pathway 
enrichment. (b) Total plasma glucose was measured via colorimetric assay to determine plasma 
glucose concentration pre- and post-gavage (each time point represents one group of mice). (c) Plasma 
glucose measured via GCMS reveals labeled versus unlabeled glucose at each time point. (d) Pathway 
distribution analysis of 13C enrichment within specific metabolic pathways in plasma, liver, and brain. 
The average 13C fractional enrichment across representative metabolites from glycolysis, tricarboxylic 
acid (TCA) cycle, amino acids, and neurotransmitters were calculated, and shown as the percent of 
total 13C enrichment across these pathways for each tissue. Values shown are mean ± SEM (n = 3–5). 
Data analyzed by unpaired t-test, p values shown on graph (b). 
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focus on glycolytic and TCA cycle intermediates as well as neurotransmitter synthesis (Figure 2a). 
The labeling of TCA cycle intermediates can provide information regarding contributions from the 
enzymes pyruvate dehydrogenase (PDH), pyruvate carboxylase (PC), and malic enzyme (ME), which 
govern pyruvate entry to the TCA cycle (Figure 2a, color coded). PDH liberates one carbon atom from 
pyruvate as CO2 and incorporates two carbons (via acetyl-CoA), while PC incorporates all three 
carbons from pyruvate. The reversible ‘malic’ enzyme reaction (malate dehydrogenase-
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oral gavage of [U-13C] glucose. (a) Schematic of metabolomics workflow for usage of stable isotope
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across these pathways for each tissue. Values shown are mean ± SEM (n = 3–5). Data analyzed by
unpaired t-test, p values shown on graph (b).
2.2. Brain Metabolites Display Varying Patterns of 13C Labeling
We next examined specific labeling patterns of 13C incorporation in the brain, with a specific
focus on glycolytic and TCA cycle intermediates as well as neurotransmitter synthesis (Figure 2a).
The labeling of TCA cycle intermediates can provide information regarding contributions from
the enzymes pyruvate dehydrogenase (PDH), pyruvate carboxylase (PC), and malic enzyme (ME),
which govern pyruvate entry to the TCA cycle (Figure 2a, color coded). PDH liberates one carbon atom
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from pyruvate as CO2 and incorporates two carbons (via acetyl-CoA), while PC incorporates all three
carbons from pyruvate. The reversible ‘malic’ enzyme reaction (malate dehydrogenase-decarboxylating)
can generate singly labeled (m+1) isotopologues via conversion of m+1 pyruvate and CO2 to form
m+1 malate (and subsequently m+1 oxaloacetate via malate dehydrogenase), that can be further
incorporated into other TCA cycle intermediates [20]. Fractional enrichment of specific metabolites
isolated from whole brain tissue over time are shown in Figure 2b–l. Metabolites associated with
glycolysis (glyceraldehyde phosphate [GAP], pyruvate, lactate, and alanine) displayed the highest
enrichment at 15 and 30 min (Figure 2b–d). Conversely, the labeling in TCA cycle intermediates
generally plateaued at 2 h and/or began to decline by 4 h (Figure 2f–i). Although technical limitations
hinder measuring oxaloacetate (OAA) directly, aspartate fractional enrichment (Figure 2i) reflects that
of OAA due to its equilibrium with aspartate [29]. Additionally, two abundant neurotransmitters
(pyroglutamic acid and GABA) displayed enrichment patterns similar to their precursor for synthesis,
glutamate, with peak enrichment at 2–4 h post-gavage (Figure 2j–l). Finally, labeling patterns among
pyruvate and citrate can be used as surrogates to estimate enzyme activity of PDH and PC [21],
calculated as (citrate m+2/pyruvate m+3) and (citrate m+3/pyruvate m+3), respectively. Our data show
increased activity of PDH relative to PC 15 min post-gavage, with decreasing contributions of both
enzymes over time reflecting the passage of the 13C-glucose bolus through the TCA cycle (Figure 2m).
Brain time course data available in Supplementary File S1.
2.3. Measuring Glucose Metabolism in an Alzheimer’s Disease Model
In order to illustrate a potential application of this oral gavage technique, we examined how
cerebral glucose metabolism is affected in the 5XFAD mouse model of Alzheimer’s disease [30].
Immediately following their final cognitive testing session, 5XFAD mice and age- and sex-matched
WT controls were given an oral gavage of [U-13C] glucose and brain tissue collected for metabolomic
analysis after 2 h (Figure 3a). The commonly used 5XFAD model of Alzheimer’s disease shows
early and significant cognitive deficits, as evidenced by decreased performance in a water maze
test of spatial learning and memory (Figure 3b,c). Interestingly, brains from 5XFAD mice exhibited
decreased fractional enrichment of fully labeled pyruvate and lactate (m+3), indicative of a reduction
in glycolysis relative to WT mice (Figure 3d,e), and further demonstrated by the reduced labeling in
serine denoted by the decreased m+2 isotopologue (Figure 3f). Additionally, glucose-derived synthesis
of the neurotransmitters GABA, N-acetylaspartate (NAA), and aspartate were significantly reduced in
the 5XFAD model relative to the WT controls (Figure 3g).
Importantly, in addition to the quantification and interpretation of stable isotope enrichment,
the datasets generated with this method can also be mined for information from total metabolic pool
sizes (regardless of labeling). To generate a more global view of metabolism in the 5XFAD brain,
we quantified the relative pool size of ~80 readily identified metabolites and analyzed these data using
Metaboanalyst [31]. A principal component analysis showed that the 5XFAD and WT mice have distinct
metabolic profiles (Figure 4a), while a volcano plot highlighted several specific metabolites that were
uniquely altered in the 5XFAD brain (Figure 4b). The most substantially altered metabolites included
threonate, adenosine monophosphate (AMP), and malate, which were all significantly reduced in the
5XFAD brain compared to WT (Figure 4c). To determine which metabolic pathways were most affected,
we performed a pathway enrichment analysis, which highlighted the pentose phosphate pathway
(PPP), carnitine synthesis, pantothenate and CoA biosynthesis, mitochondrial beta oxidation, and fatty
acid metabolism as the most significantly altered pathways between 5XFAD and WT mice (Figure 4d).
Finally, a pathway impact analysis showed several major differences between WT and 5XFAD brain
samples, highlighting changes in the concentration of metabolites considered key nodes within their
pathways. Pathways highlighted by this impact analysis included hexose metabolism (fructose,
mannose), purine metabolism, PPP, and several amino acid processing pathways (β-alanine; glycine,
serine and threonine; alanine, aspartate and glutamate; valine, leucine and isoleucine) (Figure 4e).
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Figure 2. Carbon tracing in the brain after oral gavage of [U-13C] glucose. (a) Example diagram tracing
of glucose carbon through glycolysis, TCA cycle, and neurotransmitters in whole-brain tissue from mice
receiving oral gavage of [U-13C] glucose (not all possible labeled isotopologues are shown). Carbons are
color coded based on the pathway and/or enzyme from which the carbon was derived. Grey circles: 13C from
glycolysis; green: 13C from pyruvate dehydrogenase (PDH); yellow: 13C from pyruvate carboxylase (PC);
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blue, yellow, green tricolor: 13C from malic enzyme (ME), reentry via ME, PC, or PDH; oxaloacetate
(OAA); α-ketoglutarate (α-KG); γ-aminobutyric acid (GABA). (b–l) Fractional enrichment of 13C from
glucose over time in the labeled isotopologues of pyruvate, lactate, Ala, glyceraldehyde phosphate
(GAP), citrate, fumarate, malate, Asp, Glu, pyroglutamic acid, and GABA, respectively. (m) Surrogate
enzyme activities were calculated for PDH (citrate m+2/pyruvate m+3) and PC (citrate m+3/pyruvate
m+3) in the brain, showing their respective contributions toward metabolism of [U-13C] glucose
(via pyruvate) into the TCA cycle over time. Values shown are mean ± SEM (n = 4–5) (b–m).
Data analyzed by unpaired t-tests (m). * p < 0.05; ** p < 0.01.
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gavage of [U-13C] glucose. (g) Percentage of 13C enrichment in γ-aminobutyric acid (GABA), Glu, n-
acetylaspartate (NAA), and Asp indicate de novo synthesis of neurotransmitters from glucose (shown 
as percent of average labeled isotopologues in WT). Values shown are mean ± SEM (n = 6–7). Data 
analyzed by repeated measures ANOVA (b), unpaired t-test (c,g), and multiple t-tests (d–f). * p < 0.05; 
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t-test (c,g), and multiple t-tests (d–f). * p < 0.05; ** p < 0.01.
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Data analyzed by unp ired t-test (c). * p < 0.05; ** p < 0.01.
2.4. Liver Metabolites Display Varying Patterns of 13C Labeling
We also examined 13C incorporation in the liver, detecting enriched metabolites across all time
points post-gavage. In the liver, glucose that enters glycolysis is actively further metabolized in
pathways such as the TCA cycle and amino acid biosynthesis (Figure 5a). Fully labeled (m+6)
glucose-6-phosphate (G6P) was the dominant isotopologue 15 min post-gavage, and the presence
of measurable fractions of other labelled G6P isotopologues suggests a significant amount of 13C
scrambling (Figure 5b). Enrichment of pyruvate showed a steady decline in labeling over time after
the predominate isotopologue m+3 peaked at 15 min post-gavage (Figure 5c). Lactate and alanine
labeling were more robust than pyruvate, likely a reflection of two processes where the interconversion
of lactate- and alanine-pyruvate (Cori and Cahill cycles) divert pyruvate for extrahepatic metabolism
(Figure 5d,e) [32]. Serine m+2 increased in abundance from 15 to 30 min post-gavage, likely contributed
from glycine formed through 13C cataplerosis from the TCA cycle (Figure 5f). Citrate and malate
showed direct labeling of TCA intermediates, which are used to generate amino acids like aspartate,
and as such they displayed similar fractional labeling patterns (Figure 5g–i). Finally, using our
previously established method of glycogen quantitation [33,34], we observed dynamic glycogen
enrichment in the liver and brain. Liver glycogen enrichment peaked at 30min, followed by a slow
but steady decline until 4 h post gavage, while a similar pattern was observed in brain (Figure S2,
Supplementary Materials). Liver time course data available in Supplementary File S1.
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Figure 5. Carbon tracing in the liver after oral gavage of [U-13C] glucose. (a) Diagram tracing of glucose
through central carbon metabolism pathways in the liver. Not all possible labeled isotopologues are
shown. Grey circles: 13C; white circles: 12C. (b–i) Fractional enrichment of 13C from glucose over time
in the labeled isotopologues of glucose-6-phosphate, pyruvate, lactate, Ala, Ser, citrate, malate, and Asp,
respectively. Values shown are mean ± SEM (n = 4–5).
2.5. Tracing Glucose Metabolism in a Mouse Model of Type II Diabetes
To illustrate the potential ap lication of this method in a second disease odel s st ,
leptin defic ent ob/ob mice (Lepo ), a common mouse model f obesity and type II diabetes [35].
We confirmed s veral phenotypic characteri tics of the model and then empl yed our method of
stable isotope t ac r d livery to ighlight potential changes in hepatic glucose metabolism (Figure ).
Lepob/ob mice reliably demonstrate several features of type II diabetes, including increased adiposity,
hyperlipidemia, and fatty liver, as reflected by increased bodyweight, plasma triglycerides, and hepatic
triglyceride content measurements (Figure 6b–d). To examine specific metabolic perturbations in
Lepob/ob mice, we harvested liver tissue 2 h following gavage of [U-13C] glucose. The fractional
enrichment distribution in several glycolytic intermediates were significantly altered between Lepob/ob
and WT mice. Specifically, Lepob/ob showed decreased m+6 G6P, m+3 3-phosphoglyercate (3PG),
and all labeled isotopologues of lactate (m+1, m+2, m+3; Figure 6d,e). Taken together, these results
suggest decreased glucose enrichment in downstream metabolic products from Lepob/ob mice relative
to WT, 2 h after oral gavage of [U-13C] glucose.
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Figure 6. Liver glucose metabolism in the Lepob/ob (ob/ob) obesity and type II diabetes mouse model.
(a) Experimental paradigm depicting ob/ob and WT mice receiving oral gavage of [U-13C] glucose,
2 h after which tissues and plasma were collected. (b) Bodyweight measurement shows greater body
mass of ob/ob mice relative to WT. (c,d) Triglyceride levels measured via colorimetric assay reveals
increased plasma (C) and liver (d) triglycerides levels in ob/ob mice. (e–g) Fractional labeling patterns
in glucose-6-phosphate (e), 3-phosphoglycerate (3PG; f), and lactate (g). Values shown are mean ± SEM
(n = 4–5). Data analyzed by unpaired t-test (b–d) and unpaired, multiple t-tests (d-e). * p < 0.05;
** p < 0.01; *** p < 0.001.
3. Discussion
SIRM analysis in vitro has become a widespread methodology to allow a more targeted
interrogation of perturbed metabolic pathways [36]. More recent advances have allowed the delivery of
stable isotope tracers to ex vivo tissue slices [37], small animals and even human patients. In vivo SIRM
remains a challenging task despite being a very desirable workflow and is therefore a technique still
limited to a select number of laboratories around the world. In order to facilitate wider adoption of this
valuable in vivo methodology, physiologically relevant cost-effective methods for in vivo metabolomics
analyses are needed. In the current study, we describe a simple, affordable and robust method of
in vivo SIRM in which [U-13C] glucose is delivered to mice via an oral gavage. We provide a detailed
time course of 13C incorporation into the plasma, liver and brain of mice, and further demonstrate the
utility of this technique by highlighting metabolic changes in two commonly used mouse models of
Alzheimer’s disease and type II diabetes.
In vivo SIRM is inherently complex, as the tissue metabolome is an interconnected myriad of
de novo synthesized metabolites and circulating metabolites as products of systemic metabolism.
Methods of tracer delivery via IV and IP injections or microdialysis may be more beneficial for use
of tracers such as fatty acids or triglycerides, which require longer term metabolic processing for
incorporation into downstream metabolic pathways within peripheral tissues [38]. However, because
direct infusions into circulation or tissues bypass normal gastrointestinal processing and absorption,
some physiological relevance is sacrificed. While single injections avoid the high cost associated with
continuous infusions, many preliminary trials are often necessary to obtain the optimal time point
after the one-time bolus. Furthermore, the stress due to the inherent invasiveness of such delivery
methods can further complicate results.
Other less-invasive methods currently used for administering tracers in vivo include various modes
of dietary incorporation ad libitum (normal dietary supplementation and liquid diet). These methods,
also detailed by Garcia, et al. [38], retain the physiological relevance of enteral ingestion lost
through direct infusions. Unfortunately, they share the common problems of low throughput,
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access to unique expertise, and most importantly high cost (often upwards of over $300 per mouse).
For example, the liquid diet isotopic tracer delivery method allows SIRM analysis at isotopic steady
state beyond central carbon metabolism, is minimally invasive, and permits ad libitum consumption
of tracer [20]. However, there are two major biological drawbacks of this technique. First, the long
(14–24 h) enrichment time allows for extensive isotopic exchange between de novo synthesized and
circulating metabolites and results in isotopic scrambling in host tissues, thus substantially complicating
interpretation. Second, the method is limited to animals with normal eating habits, i.e., not sick or
behaviorally abnormal. For example, animals that carry xenografted tumors or overt neurological
manifestations cannot be studied using the liquid diet.
An ideal in vivo delivery method would be cost effective, minimally invasive, with improved
throughput; and we designed the gavage method described herein with all three parameters in mind.
While dosing can easily be modified using the gavage method, the current experimental design was
based on the principle of the commonly used oral glucose tolerance test (OGTT) (2 g of glucose per kg
of bodyweight (40 mg/animal of 20 g)). This dose is based on clinical tests routinely performed on
humans [39], and is commonly used in mouse studies of obesity, insulin resistance and diabetes [40].
The dietary glucose bolus is delivered via gavage without trauma or anesthesia [41], and can easily
allow analysis of upwards of 50 animals per day (this study utilized 30 animals over the course of six
hours). Thus, we anticipate that this delivery method will allow greater facilitation and utilization of
in vivo SIRM in the research community. As this method is based off the OGTT routinely employed in
the clinic, we anticipate that similar time course studies can be conducted in human subjects. Indeed,
tracing of 13C substrates has been applied by several groups in human studies, as nicely reviewed
by Garcia, et al. [38]. A primary drawback for this approach, however, is that while multiple plasma
samples can easily be harvested and analyzed, analysis of human tissue can only occur ex vivo
(as opposed to a 13C NMR based method) and thus requires collection of excised tissue (ex. surgically
resected tumors or biopsies).
Here, we performed a time course of enrichment from [U-13C] glucose in multiple tissues,
highlighting windows of isotopic distribution and utility to simultaneously interrogate multiple organs
from a single mouse. We demonstrate the broad applicability of this method in commonly used mouse
models of Alzheimer’s disease (5XFAD) and type II diabetes (Lepob/ob). We showed how decreased
glucose metabolism influences de novo neurotransmitter synthesis in the 5XFAD mouse model which
may correlate with cognitive deficits. The 5XFAD mouse model has been shown to display glucose
hypometabolism, as detected by a decreased FDG-PET signal [42]. Glucose hypometabolism is a
common feature of AD that can occur in tandem with reduced cerebral blood flow thereby affecting
metabolism by limiting oxygen availability to certain regions [43]. As a cell’s metabolic activity
(and thus the pattern of 13C enrichment detected in an experimental setting) is clearly affected by
availability of oxygen for mitochondrial respiration, researchers should consider potential changes in
oxygen consumption in their disease model of choice. For example, reduced mitochondrial respiration
has been reported in the brain of 5XFAD mice [44], and it is possible that these decreases in oxygen
consumption are reflected in our data showing decreased 13C labeling of neurotransmitters synthesized
from TCA cycle intermediates in 5XFAD mice compared to WT controls. Decreases in glycolysis shown
in the Lepob/ob model are likely attributed to hampered insulin sensitivity and may also result in part
from the increased hepatic and systemic adiposity. Interestingly, we did not observe striking differences
in fractional labeling patterns of TCA cycle intermediates with either mouse model, which is surprising
given the known mitochondrial dysfunction associated with both the 5XFAD and Lepob/ob mice [45,46].
However, metabolism of glucose by the TCA cycle may be further resolved with intermediary time
points between 30 min and 2 h as presented herein. Furthermore, as our measurements were taken at
early post-prandial time points, we did not observe any signs of liver gluconeogenesis in plasma or liver.
This is likely a reflection of post-prandial activation of pathways of glucose storage (e.g., glycogenesis,
as shown in Figure S2). However, analysis of later time points would likely offer more insight into the
gluconeogenic role of the liver.
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It should also be noted that any potential differences in TCA cycle intermediates inherent to either
mouse model could be obscured given the rapid onset of tissue hypoxia, which occurs just seconds
post-mortem. Although some degree of tissue hypoxia is likely unavoidable without a microwave
fixation system, it can be mitigated with expeditious tissue collection. Thus, despite the relatively short
period (less than 15 sec) between euthanasia and freezing of tissue employed in this study, artifactual
changes in metabolism due to tissue hypoxia remain a concern with this and many other in vivo
metabolomic approaches.
Altogether, we detected 80 metabolites across more than 10 metabolic pathways, of which
15 metabolites involved directly in central carbon metabolism displayed various isotopic distributions
of 13C enrichment from [U-13C] glucose. When applied to animal models of disease, the extensive
information made available through this method affords substantial potential in characterizing
metabolic networks affected by diseases that may lead to elucidating metabolic targets for therapeutic
interventions. While the GCMS employed in the current study is relatively affordable, it is limited in
the number of metabolites detected. A more robust mass spectrometer could be used to assess isotopic
enrichment in additional pathways such as the PPP and nucleotide metabolism.
Another limitation is that while we assume minimal invasiveness through previously established
plasma corticosterone levels after gavage [41], we still anticipate an increase in stress through handling
of the mice. However, based on this literature, we expect that the stress level is much lower compared
to IV/IP injection and/or anesthetized animals—and can be further mitigated by conditioning the
mice through repeated handling. While this delivery method has great potential to uncover much of
the in vivo metabolome, tissue heterogeneity presents concerns of discerning specific contributions
from distinct subpopulations of cells. Performing metabolomics on cell-sorted populations might
alleviate such concerns, but current techniques are encumbered with metabolism-altering effects
of sorting [47]. Imaging techniques like matrix assisted laser desorption/ionization (MALDI) and
desorption electrospray ionization (DESI) might provide an alternative solution for tissue heterogeneity
through spatial resolution of metabolites in prepared tissues. Application of MALDI or DESI in
tissue obtained from an isotopic enriched animal could provide unique insight into metabolism at the
micro-region and/or cell population level, representing an important and exciting next step to better
understanding the in vivo metabolome.
4. Conclusions
In conclusion, using an oral gavage to administer stable isotope tracers in mice is an effective
tool for studying metabolism in vivo with broad applicability. We demonstrate a detailed time course
for a number of metabolites and metabolic pathways following [U-13C] glucose delivery via oral
gavage that shows sufficient incorporation of 13C into major metabolically active organs. We caution
that these data be used as a starting point—a recommendation to guide future study designs. Many
aspects of experimental conditions (phenotype, pharmacological intervention, and tracer selection)
can greatly affect metabolite turnover rate and isotopic distribution, and researchers should carefully
select parameters with these factors in mind. Future experiments should include gavage of other
stable isotope tracers such as 13C- or 15N-glutamine and other amino acids, 13C-ketones, and 13C-fatty
acids to trace their distribution and detail their time course. Finally, this method can be easily adapted
further with expanded time points and sequential gavages to determine flux analyses and nutrient
turnover rate of glucose and other tracers.
5. Materials and Methods
5.1. Animals
All animal procedures were performed in accordance with institutional regulations and the
institutional animal care and use ethics committee at the University of Kentucky College of Medicine
(Protocol #2016-2569; approval date: 1 March 2020). Female wild type (WT) mice of C57BL/6
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background (14 weeks old), ordered from the Jackson Laboratory (Bar Harbor, ME, USA) were housed
in a climate-controlled environment with a 14/10-h light/dark cycle with water and regular chow diet
ad libitum. Sex- and age-matched Lepob (ob/ob), ordered from the Jackson Laboratory (Bar Harbor,
ME, USA), were used as a liver glucose metabolism comparison to WT mice. Sex- and age-matched
homozygous 5XFAD, ordered from the Jackson Laboratory (Bar Harbor, ME, USA), mice were used for
behavioral testing and metabolomics analysis as a comparison to WT mice.
5.2. Gavage of [U-13C] Glucose Solution
[U-13C] Glucose (Cambridge Isotope Laboratories, Tewksbury, MA, USA) was dissolved in ddH2O
(Millipore Milli-Q, Bedford, MA, USA) based on the average mouse cohort bodyweight (2 g [U-13C]
glucose/kg bodyweight), based on diabetic glucose tolerance testing. Mice were fasted for 2–4 h then
administered a 250 µL volume of glucose solution via oral gavage. Blood and tissues (brain and
liver) were collected 15 min, 30 min, 2 h, or 4 h post-gavage, detailed below. Blood and tissue were
also collected from mice following starvation period (no gavage) and 4 h following either saline or
non-labeled glucose gavage for use as controls for 13C labeling and gavage protocol.
5.3. Plasma and Tissue Collection
Following respective post-gavage incubation periods, mice underwent cervical dislocation and
decapitation after which brain and liver were promptly removed and frozen in liquid nitrogen.
Blood was collected via trunk bleed into tube containing 0.5M EDTA (Thermo Fisher Scientific,
Waltham, MA, USA) and kept on ice until plasma was separated via centrifugation at 1300 × g for
10 min at 4 ◦C. The plasma layer (supernatant) was collected in two aliquots then flash frozen in
liquid N2 until derivatization protocol, detailed below. Following prompt removal of brain and liver,
tissues were washed in PBS (Bio-Rad, Hercules, CA, USA) twice, then ddH2O and quickly blotted dry
before submersion in liquid N2, and stored at −80 ◦C until further processing.
5.4. Glucose Colorimetric Assay
Blood glucose concentrations were measured in plasma samples from WT mice using a glucose
colorimetric assay (Cayman Chemical, Ann Arbor, MI, USA). The procedure was conducted according
to manufacturer’s protocol. Briefly, plasma samples were thawed on ice then a volume of 15 µL per
sample and manufacturer’s standards were added to a 96-well plate followed by addition of 85 µL
assay buffer. Following addition of enzyme mixture, 100 µL, the plate was incubated for 10 min at
37 ◦C. After which a plate reader was used to read the absorbance at 510 nm and sample absorbances
were compared with the standard curve to determine concentrations.
5.5. Triglyceride Assay
Blood and liver triglyceride concentrations were measured in WT and Lepob/ob using a triglyceride
colorimetric assay (Cayman Chemical, Ann Arbor, MI, USA). Plasma samples were thawed on ice and
diluted 1:9 with sodium phosphate assay buffer. Liver samples were thawed on ice and approximately
150 mg was finely minced and homogenized in 1 mL of diluted NP40 reagent containing proteinase
inhibitors provided by the manufacturer. The remaining procedure was conducted according to
manufacturer’s protocol. Briefly, liver samples were centrifuged at 10,000× g for 10 min at 4 ◦C, then the
supernatant was diluted 1:4 with NP40. A volume of 10 ul was used for samples and triglyceride
standards followed by addition of reaction mixture and 15 min incubation at room temperature.
The absorbance at 540 nm was read using a plate reader at 540 nm and sample absorbances were
compared with the standard curve to determine concentrations.
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5.6. Sample Preparation for GCMS Analysis
All tissues were handled on liquid nitrogen when removed from cryostorage at −80 ◦C. Brain and
liver samples were removed from cryostorage and pulverized to 10 µm particles in liquid N2
using a Freezer/Mill Cryogenic Grinder (model 6875D, SPEX SamplePrep, Metuchen, NJ, USA).
Eighty microliters of plasma were extracted with 80 µL HPLC-grade MeOH (containing 40 µM
L-norvaline [Sigma-Aldrich, St. Louis, MO, USA] for internal standard; Sigma-Aldrich, St. Louis, MO,
USA). Approximately 60 mg of powdered tissue was removed with a micro spatula to a new tube and
extracted with 50% MeOH (20 µM L-norvaline). Following addition of MeOH, mixtures were placed on
ice for 20 min and briefly vortexed at 5 min intervals. Following centrifugation at 24,000× g for 10 min
at 4 ◦C the aqueous phase containing polar metabolites was isolated to a separate tube, the resulting
pellet briefly dried at 10−3 mBar using a SpeedVac (Thermo Fisher Scientific, Waltham, MA, USA) to
evaporate remaining MeOH then reconstituted in RIPA buffer (Sigma-Aldrich, St. Louis, MO, USA)
followed by BCA Protein Assay Kit (Pierce; Thermo Fisher Scientific, Waltham, MA, USA) for protein
concentration. The polar metabolites were dried at 10−3 mbar followed by derivatization. The dried
polar metabolite pellet was derivatized by a two-step methoxyamine protocol first by addition of
50 µL methoxyamine HCl (Sigma-Aldrich, St. Louis, MO, USA) in pyridine (20 mg/mL; Sigma-Aldrich,
St. Louis, MO, USA) followed by 60 min dry heat incubation at 60 ◦C. Samples were then transferred
to v-shaped glass chromatography vials (Agilent Technologies, Santa Clara, CA, USA) and sequential
addition 80 µL N-methyl-trimethylsilyl-trifluoroacetamide (MSTFA; Thermo Fisher Scientific, Waltham,
MA, USA) followed by 60 min dry heat incubation at 60 ◦C. The samples were allowed to cool to room
temperature then analyzed via GCMS.
5.7. Glycogen Preparation for GCMS Analysis
Following removal of polar metabolites by 50% MeOH, the biomass fraction containing protein
and glycogen were first resuspended in ddH2O followed by the addition of equal part 2N hydrochloric
acid (HCl; Sigma-Aldrich, St. Louis, MO, USA). Samples were vortexed thoroughly and incubated at
95 ◦C for 2 h to allow the hydrolysis of glycogen to single glucose units. The reaction was quenched
with 100% MeOH with 40 µM L-norvaline, samples were incubated on ice for 30 min, and the
supernatant collected after centrifugation at 21,130× g at 4 ◦C for 10 min. The collected supernatant was
subsequently dried by vacuum centrifuge at 10−3 mBar followed by derivatization similar to above.
5.8. GCMS Quantitation
GCMS (Agilent Technologies, Santa Clara, CA, USA) protocols were similar to those described
previously [48,49] except a modified temperature gradient was used for GC: Initial temperature was
130 ◦C, held for 4 min, rising at 6 ◦C/min to 243 ◦C, rising at 60 ◦C/min to 280 ◦C, held for 2 min.
The electron ionization (EI) energy was set to 70 eV. Scan (m/z: 50–800) and full scan mode were
used for metabolomics analysis. Mass spectra were translated to relative metabolite abundance
using the Automated Mass Spectral Deconvolution and Identification System (AMDIS) software
matched to the FiehnLib metabolomics library (available through Agilent) for retention time and
fragmentation pattern matching with a confidence score of >80 [13,50–52]. Quantitation was performed
and corrected for natural abundance using the Data Extraction for Stable Isotope-labelled metabolites
(DExSI; https://github.com/DExSI/DExSI) with a primary ion and at least 2 or more matching qualifying
ions. Relative abundance was corrected for recovery using L-norvaline and adjusted to protein input
from BCA measure to correct for any differences in tissue quantity used for extraction.
5.9. Metabolomics Data Analysis
Fractional enrichment of each metabolite was calculated as the relative abundance of each
isotopologue relative to the sum of all other isotopologues. Pathway distribution analysis was
determined for glycolysis, TCA cycle, amino acid, and neurotransmitter synthesis pathways and
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calculated as the average percentage of 13C-labeled isotopologues (m+1 + m+2 . . . + m+n) of metabolites
within each pathway relative to the 13C enrichment across all other pathways. For volcano plot,
principal component analysis, fold enrichment plot and pathway impact analyses, the online tool
Metaboanalyst (https://www.metaboanalyst.ca) was used. For pathway impact analysis, data were
filtered using interquartile range (IQR) function and scaled using auto-scaling, in which mean-centered
values were divided by the standard deviation of each variable. Global test’ and ‘Relative Betweenness
Centrality’ parameters were used to determine metabolic pathway ‘hub’ importance.
5.10. Animal Cognitive Testing
Cognitive function was tested in WT and 5XFAD mice using a Morris water maze as previously
described [53]. Trials were performed in a black pool (diameter 121.5 cm) filled with opaque water
with a temperature of 22 ◦C and lighting between 41.0 and 43.0 lux. Mice were individually housed
and allowed to acclimate to cages for 30 min prior to trial start. Mice were given two sessions per
day, and each session consisted of two trials. Each session was separated by 3 h, and each trial by
10 min. Over a 4-day span, mice were trained during “Hidden Platform” trials to locate an “escape”
platform (diameter 10 cm) submerged just under the surface of the water in the “target” quadrant.
“Hidden Platform” trials lasted 60 sec, or until the mouse located the platform and remained on it for
3 sec. The drop location (where the mice were placed into the maze) was randomized for each trial,
and never included a location within the “target” quadrant. For all consecutive “Hidden Platform”
trials, the platform location was not changed. Visual cues (38 × 38 cm) were placed at the borders of
each quadrant for reference. Spatial memory was assessed 72 h following completion of the “Hidden
Platform” trials. During the “Probe” trial, the hidden platform was removed, and spatial memory was
assessed by measuring cumulative distance from the platform location. Mice then received 2 more
days of “Hidden Platform” training followed by a second “Probe.” Upon completion of the final
“Probe” trial, mice received 2 “Visible Platform” trials with a colored flag (height of 18 cm) cue placed
on the platform. All trials were recorded with a camera and analyzed using Ethovision XT (Noldus
Information Technology, Leesburg, VA, USA).
5.11. Statistical Analysis
All data are expressed as mean values +/− standard error. Comparisons between two groups
were analyzed by unpaired, two-tailed t-test or multiple unpaired, two-tailed t-tests (one per row)
for comparisons with multiple isotopologues. Multiple time points (animal cognitive testing) were
analyzed using ANOVAs or repeated measures ANOVA (time × groups). Statistical significance was
determined using an error probability level of p < 0.05 corrected using the two-stage linear step-up
procedure of Benjamini, Krieger and Yekutieli, with Q = 1%. Statistical details can be found in figure
legends for each figure, all statistical analyses were calculated using GraphPad Prism 8 software
(GraphPad Software, San Diego, CA, USA).
Supplementary Materials: The following figures and file are available online at http://www.mdpi.com/2218-1989/10/
12/501/s1: Figure S1: Plasma 13C enrichment in metabolites over time. Figure S2: Liver glycogen flux from 13C glucose.
Supplementary File S1. Raw data as relative abundance (natural abundance stripped) and fractional enrichment.
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